Braveheart Bio, Inc. (BRVE) financials — revenue, cash, debt and margins

Braveheart Bio, Inc. (BRVE) financials — revenue, cash, debt and margins — InspectStocks

Key figures

Trailing twelve months where a flow is involved, latest reported balance where it is not.

Valuation

Market cap: $159.6M
P/E (TTM): —
Price / sales: —
EV / EBITDA: —
Price / book: —

Cash flow

FCF yield: —
SBC-adjusted FCF yield: —
SBC impact: —
Stock compensation (TTM): —

Margins & growth

Profit margin: —
Operating margin: —
Quarterly revenue (year on year): —
Quarterly earnings (year on year): —

Balance sheet

Cash & investments: $122.8M
Debt: $575K
Net cash / (debt): $122.3M

What it owns and what it owes

Both on one scale, because both are money — the bar that is taller is the one that matters.

Cash and debt

Cash & InvestmentsTotal Debt

Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.

The rest of the series

Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each quarter on its own, so seasonal highs and lows are visible.

Profit

-$14.99MQ2 2026-5.0%

What was left after every cost, including tax. Each quarter on its own, so seasonal highs and lows are visible.

Profit per share

-$2.51Q2 2026-1,692.9%

The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each quarter on its own, so seasonal highs and lows are visible.

Shares outstanding

7.4MQ2 2026+165.1%

How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each quarter on its own, so seasonal highs and lows are visible.

About Braveheart Bio, Inc.

Ticker: BRVE
SEC classification: Pharmaceutical Preparations (2834)
Listed on: Nasdaq
Incorporated in: DE
Financial year ends: December 31
Filer size: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

About this data

Everything above comes from Braveheart Bio, Inc.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.

Not reported by this filer: Total Revenue, Cost of Revenue, Gross Profit, R&D Expense, Interest Expense, Income Tax Expense, Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Short-term Investments, Inventory, Receivables, Long-term Debt (noncurrent), Long-term Debt (current), Short-term Borrowings, Borrowings (total), Finance Lease (current), Finance Lease Liabilities (total), Finance Lease (noncurrent), Dividends paid, Depreciation, Amortization of Intangibles, and Share Repurchases. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.